PASINI v2.1

• Research type

  Research Study

• Full title

  Phenotyping of blood samples to detect Autoimmune Signature following Ipilimumab and Nivolumab Immunotherapy

• IRAS ID

  251026

• Contact name

  David Chao

• Contact email

  dchao@nhs.net

• Sponsor organisation

  University College London

• Clinicaltrials.gov Identifier

  Z6364106/2018/10/66, Data Protection Registration

• Duration of Study in the UK

  2 years, 11 months, 31 days

• Research summary

  Immunotherapy is a new form of cancer treatment harnessing the immune system to attack the cancer. The main side effects are autoimmune where the body's immune system targets the healthy organs instead of the cancer. As we combine immunotherapy drugs to improve outcomes the autoimmune side effects have become limiting but we cannot predict which patients are more likely to suffer such side effects, or to benefit from treatment. This study will analyse blood samples from patients receiving immunotherapy with combination drugs to see if we can find markers to make such predictions.

• REC name

  East Midlands - Leicester Central Research Ethics Committee

• REC reference

  18/EM/0342

• Date of REC Opinion

  5 Dec 2018

• REC opinion

  Further Information Favourable Opinion